Dermira Leans On Patient Experience With Hyperhidrosis As It Readies For Qbrexza Launch
Executive Summary
Chief Commercial Officer Lori Lyons-Williams tells Scrip that patient stories were the tipping point for many payers considering Qbrexza's $550 per month price. Dermira's also catering to patients with co-pay assistance and a commitment not to raise pricing until after 2019.
You may also be interested in...
Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
No Sweat – Hyperhidrosis Patients Seek Broader Approvals; Botox Access An Issue
US FDA not looking to reduce attendance at third-party patient meetings, which deliver 'bang for the buck.' Excessive sweating is first externally led PFDD meeting for a more common condition.